AI CAPITAL INTELLIGENCE
Isomorphic Labs · Series B · USD 2,100,000,000 · 2026-05-12
Financing facts, at a glance
Isomorphic Labs: financing disclosed on 2026-05-12, Series B, USD 2,100,000,000. Named investors: Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund. This is the amount disclosed for the financing, not a company valuation or an individual investor commitment.
Isomorphic Labs is recorded in the Industry AI / Drug discovery & life sciences segment. The disclosed financing is Series B, with an amount of USD 2,100,000,000. Named investors include Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund.
- Disclosed company name
- Isomorphic Labs
- Disclosure date
- 2026-05-12
- Round
- Series B
- Financing amount
- USD 2,100,000,000
- Market coverage
- Outside China
- Sector
- Industry AI / Drug discovery & life sciences
- Product form
- Enterprise software
Disclosed investors
Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund
Original sources
Record reviewed as of . Reported ranges and lower bounds are retained. Financing proceeds are not company valuation.